Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
DLBCL
extranodal lymphoma
gastric DLBCL
gastric lymphoma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
revised:
03
04
2024
received:
03
02
2024
accepted:
04
04
2024
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71-95) and 91% (95% CI: 75-97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non‐Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3861–3873.
Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–2473.
Engels EA. Infectious agents as causes of non‐Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:401–404.
Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350:239–248.
Hirabayashi M, Traverse‐Glehen A, Combes J‐D, Clifford GM, de Martel C. Estimating the prevalence of Epstein‐Barr virus in primary gastric lymphoma: a systematic review and meta‐analysis. Infect Agent Cancer. 2023;18:8.
Nagakita K, Takata K, Taniguchi K, Miyata‐Takata T, Sato Y, Tari A, et al. Clinicopathological features of 49 primary gastrointestinal diffuse large B‐cell lymphoma cases; comparison with location, cell‐of‐origin, and frequency of MYD88 L265P. Pathol Int. 2016;66:444–452.
Couto ME, Oliveira I, Domingues N, Viterbo L, Martins Â, Moreira I, et al. Gastric diffuse large B‐cell lymphoma: a single‐center 9‐year experience. Indian J Hematol Blood Transfus. 2021;37:492–496.
Frick M, Bettstetter M, Bertz S, Schwarz‐Furlan S, Hartmann A, Richter T, et al. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Leuk Lymphoma. 2018;59:1260–1263.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
Matysiak‐Budnik T, Fabiani B, Hennequin C, Thieblemont C, Malamut G, Cadiot G, et al. Gastrointestinal lymphomas: French intergroup clinical practice recommendations for diagnosis, treatment and follow‐up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis. 2018;50:124–131.
Kuo S‐H, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, et al. Helicobacter pylori eradication therapy is effective in the treatment of early‐stage H. pylori‐positive gastric diffuse large B‐cell lymphomas. Blood. 2012;119:4838–4844; quiz 5057.
Seymour JF, Anderson RP, Bhathal PS. Regression of gastric lymphoma with therapy for Helicobacter pylori infection. Ann Intern Med. 1997;127:247.
Fregonese B, Hajj C, Gonzalez S, Lee J, Boe L, Imber BS, et al. Radiation therapy in the management of primary gastric diffuse large B‐cell lymphomas: long‐term outcomes of 82 patients. 65th ASH Annual Meeting Abstracts 142: 6281; 2023.
Jones G, Plastaras JP, Ng AK, Kelsey CR. The evolving role of radiation therapy in DLBCL: from early‐stage to refractory disease. Oncology (Williston Park). 2022;36:718–727.
Avilés A, Nambo MJ, Neri N, Huerta‐Guzmán J, Cuadra I, Alvarado I, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg. 2004;240:44–50.
Yang H, Wu M, Shen Y, Lei T, Mi L, Leng X, et al. Treatment strategies and prognostic factors of primary gastric diffuse large B cell lymphoma: a retrospective multicenter study of 272 cases from the China Lymphoma Patient Registry. Int J Med Sci. 2019;16:1023–1031.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
Zhang L, Huang H, Wang Z, Fang X, Hong H, Chen Y, et al. A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large‐B cell lymphoma during treatment with immunochemotherapy. Cancer Med. 2023;12:6924–6934.
Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B‐cell lymphoma in the rituximab era. Blood. 2021;137:39–48.
Zhang S, Wang L, Yu D, Shen Y, Cheng S, Zhang L, et al. Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution. World J Surg Oncol. 2015;13:246.
Sbitti Y, Ismaili N, Bensouda Y, Kadiri H, Ichou M, Errihani H. Management of stage one and two‐E gastric large B‐cell lymphoma: chemotherapy alone or surgery followed by chemotherapy? J Hematol Oncol. 2010;3:23.
Ma'koseh M, Farfoura H, Abufara A, Elmusa R, Hushki A, Faqeer N, et al. Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP. Hematology. 2023;28:2198898.
Avilés A, Castañeda C, Cleto S, Neri N, Huerta‐Guzmán J, Gonzalez M, et al. Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm. 2009;24:25–28.
Fernández‐Rodríguez C, Bellosillo B, García‐García M, Sánchez‐González B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B‐cell lymphoma. Leukemia. 2014;28:2104–2106.
Curran OE, Poon MTC, Gilroy L, Torgersen A, Smith C, al‐Qsous W. MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: a single‐center experience. Neurooncol Adv. 2021;3:vdab090.
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B‐cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033.
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, et al. R‐CHOP with dose‐attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Exp Hematol Oncol. 2012;1:30.
Juárez‐Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;25:1073274818778256.
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K. RCHOP therapy overcome gastric diffuse large B cell lymphoma without surgery. Exp Hematol Oncol. 2010;116:1760.
Poeschel V, Held G, Ziepert M, Witzens‐Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B‐cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non‐inferiority trial. Lancet. 2019;394:2271–2281.
Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R‐CHOP 14 with or without radiotherapy in nonbulky limited‐stage diffuse large B‐cell lymphoma. Blood. 2018;131:174–181.
Inaba K, Kushima R, Murakami N, Kuroda Y, Harada K, Kitaguchi M, et al. Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B‐cell lymphoma. BMC Cancer. 2013;13:499.
Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, et al. Favorable radiation field decrease in gastric marginal zone lymphoma: experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). Strahlenther Onkol. 2019;195:544–557.
Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and gastric cancer: pathogenetic mechanisms. Int J Mol Sci. 2023;24:2895.
Ben Abdallah K, Ben Mohamed A, Yacoubi M, Khsiba A, Dougaz A, Chelbi E, et al. Post‐chemotherapy gastric obstruction in diffuse large B‐cell lymphoma: endoscopic dilation can fix it! Case Rep Gastroenterol. 2022;16:301–307.
Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, et al. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013;24:2439–2443.
Adams HJA, Nievelstein RAJ, Kwee TC. Prognostic value of complete remission status at end‐of‐treatment FDG‐PET in R‐CHOP‐treated diffuse large B‐cell lymphoma: systematic review and meta‐analysis. Br J Haematol. 2015;170:185–191.
Kang HJ, Lee HH, Jung SE, Park KS, O JH, Jeon YW, et al. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B‐cell lymphoma treated with R‐CHOP chemotherapy. PLoS One. 2020;15:e0238807.